Increase in the incidence of invasive fungal infections due to Volvariella Volvacea

• Published in: European journal of clinical microbiology & infectious diseases Vol. 43; no. 5; pp. 1031 - 1036
• Main Authors: Li, Feng-Zeng, Jia, Meng, Chen, Ai-Jun, Fang, Sheng
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2024; Springer Nature B.V
• Subjects: Aged; Antifungal agents; Antifungal Agents - therapeutic use; Biomedical and Life Sciences; Biomedicine; Blood cancer; Brief Report; Female; Fungal infections; Fungi; Fungicides; Humans; Immunocompromised Host; Immunosuppression; Incidence; Internal Medicine; Invasive Fungal Infections - drug therapy; Invasive Fungal Infections - epidemiology; Invasive Fungal Infections - microbiology; Invasive Fungal Infections - mortality; Invasiveness; Literature reviews; Male; Medical Microbiology; Middle Aged; Volvariella; Volvariella - genetics; Invasive fungal infections; Cutaneous leukocytoclastic vasculitis; Incidence; Volvariella Volvacea
• ISSN: 0934-9723; 1435-4373; 1435-4373
• DOI: 10.1007/s10096-024-04800-3

Purpose : We aimed to show the increasing incidence of invasive fungal infections due to Volvariella Volvacea in patients with immunosuppression. Methods : We present a case of an invasive fungal infection caused by Volvariella volvacea , and summarize the clinical and pathological features based on this case and a review of the literature. Results : A total of seven patients with IFIs due to Volvariella Volvacea have been reported in the literature. The majority of cases have been obtained between 2019 and 2022. Including our case, they all had acquired immunosuppression. The lung and brain were the most commonly affected organs. All eight of these patients received antifungal therapy, but five still died one to seven months after occurrences of IFIs. Conclusion : The incidence of invasive fungal infections due to Volvariella Volvacea is increasing in recent years. It mainly occurred in patients with immunosuppression, especially in patients with malignant hematological cancers, and increased mortality.